Sensus Healthcare, Inc. (NASDAQ:SRTS) Short Interest Down 18.1% in November

Sensus Healthcare, Inc. (NASDAQ:SRTS) was the recipient of a significant drop in short interest in November. As of November 30th, there was short interest totalling 486,100 shares, a drop of 18.1% from the November 15th total of 593,700 shares. Approximately 3.7% of the shares of the stock are short sold. Based on an average daily volume of 161,300 shares, the short-interest ratio is presently 3.0 days.

Sensus Healthcare Stock Down 3.9 %

SRTS traded down $0.33 on Friday, hitting $8.16. The company had a trading volume of 220,473 shares, compared to its average volume of 274,185. The company has a market cap of $133.73 million, a PE ratio of 14.32 and a beta of 1.16. Sensus Healthcare has a 12-month low of $2.14 and a 12-month high of $9.33. The business’s fifty day simple moving average is $7.46 and its 200 day simple moving average is $6.44.

Analysts Set New Price Targets

SRTS has been the subject of a number of research analyst reports. Maxim Group raised their price objective on Sensus Healthcare from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Friday, November 15th. HC Wainwright raised their price objective on Sensus Healthcare from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, November 18th.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of SRTS. Truvestments Capital LLC purchased a new position in shares of Sensus Healthcare during the third quarter valued at approximately $32,000. Chapin Davis Inc. bought a new stake in shares of Sensus Healthcare during the second quarter valued at approximately $53,000. XTX Topco Ltd bought a new stake in shares of Sensus Healthcare during the second quarter valued at approximately $95,000. Cubist Systematic Strategies LLC bought a new stake in shares of Sensus Healthcare during the second quarter valued at approximately $156,000. Finally, Acadian Asset Management LLC raised its stake in shares of Sensus Healthcare by 578.6% during the second quarter. Acadian Asset Management LLC now owns 45,124 shares of the company’s stock valued at $239,000 after acquiring an additional 38,474 shares in the last quarter. Hedge funds and other institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.